Q3 2024 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2024-11-14 · accession 0001104659-24-118921
$484.0M
Reported value
28
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $70.4M | 14.6% | 4,408,379 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $44.8M | 9.25% | 1,752,174 | Common | SOLE |
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $38.8M | 8.01% | 9,913,168 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $36.4M | 7.51% | 2,353,304 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $33.7M | 6.97% | 1,231,619 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $23.9M | 4.95% | 478,972 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $22.1M | 4.56% | 939,298 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $20.5M | 4.25% | 1,285,000 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $19.6M | 4.05% | 646,524 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $19.6M | 4.04% | 340,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $16.9M | 3.49% | 497,270 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $16.8M | 3.46% | 736,595 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $15.0M | 3.11% | 237,560 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $14.8M | 3.05% | 797,600 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $14.8M | 3.05% | 5,405,404 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $14.2M | 2.94% | 282,313 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $12.0M | 2.48% | 357,733 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $8.7M | 1.79% | 476,200 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $8.4M | 1.73% | 1,050,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $6.1M | 1.25% | 561,854 | Common | SOLE |
| 810648105 | SCPH | SCPHARMACEUTICALS INC | $5.5M | 1.13% | 1,200,647 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $4.5M | 0.92% | 6,361,723 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $4.2M | 0.88% | 3,630,724 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $3.8M | 0.79% | 572,665 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $3.8M | 0.79% | 541,666 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $2.5M | 0.51% | 1,305,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $1.8M | 0.37% | 490,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $609,794 | 0.13% | 56,725 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.